Any time a stock moves down 75% over a given period of time, investors have reason to be concerned. When such a move happens in a given trading day, it’s time to ring the alarm bells. For investors in ...

In this article you are going to find out whether hedge funds think Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) is a good investment right now. We like to check what the smart money thinks first ...

Short selling biotechnology stocks is a dangerous game to play. However, Deciphera Pharmaceuticals (NASDAQ:DCPH) has been a boon to the bears as DCPH stock is far below its peak price. Source: Iryna ...

Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge ...

The shares of Deciphera Pharmaceuticals (DCPH) have performed well in 2022, as they are up 40.4% while most healthcare stocks are down. Nevertheless, I would not buy shares of this stock due to a lack ...

Deciphera's ripretinib failed a critical trial. The stock has been decimated. Although the company is struggling to make a comeback, it will take time. Looking for more investing ideas like this one?

Deciphera Pharmaceuticals, Inc. DCPH reported third-quarter 2023 loss of 58 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents. In the year-ago quarter, DCPH had ...

One stock that might be an intriguing choice for investors right now is Deciphera Pharmaceuticals, Inc. DCPH. This is because this security in the Medical – Biomedical and Genetics space is seeing ...

Our estimates show that Qinlock 2L KIT exon 11+17/18 mutation indication sales guidance is unlikely to be achieved due to fractional incidence. Deciphera Pharmaceuticals is expecting a Phase III ...

The firm's stomach cancer treatment met its main goal in a late-stage study The shares of biotech name Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) have more than doubled this morning after the ...